Active Filter(s):
Details:
Through the acquisition, Curi will gain access to Dana’s AI/ML-based platforms including PhenoLearn™, a deep learning platform for modeling cell and tissue phenotypes; Pulse™, an automated platform for contractility analysis of beating cardiomyocytes; and PhenoTox™.
Lead Product(s): Human iPSC-derived cardiomyocytes
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Curi Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 23, 2020